GenSight Biologics

GenSight Biologics is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company recently submitted the Marketing Authorisation Application for its lead product LUMEVOQ®, a gene therapy for treating Leber Hereditary Optic Neuropathy caused by a mutated ND4 mitochondrial gene, in Europe and expects to have top-line results from its pivotal trial for the US available in early 2021. Its second product GS030, which applies optogenetics to treat retinitis pigmentosa, is in Phase I/II trials.

Visit sponsor site


To view all of our sponsors, please click here